Interactive digital breathing game and device for children with bronchiectasis
Official title: Development of an Interactive Digital Respiratory Game and Device and Investigation of Its Effectiveness in Children With Bronchiectasis
Run by Atlas University · NCT06897761 · Data updated 2026-11-12
We will test an interactive digital breathing game and paired device to help children aged 7–18 with bronchiectasis do airway-clearing exercises at home without a physiotherapist.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 7 Years to 18 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Atlas University Academic / other |
| Locations | 1 site (Istanbul) |
| Status | Recruiting |
| Started | October 7, 2025 |
| Main results expected | December 7, 2025 |
| Study ends | January 15, 2026 |
| Registry record updated | January 6, 2026 |
| Trial ID | NCT06897761 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children 7–18 years old with bronchiectasis who are clinically stable, have access to a smartphone/tablet/computer, and have no cognitive or major comorbid conditions that would prevent using the system.
✕Probably not a fit
Patients with recent supervised physiotherapy, history of lung or liver transplant, active exacerbations or infections, significant cognitive impairment, or concurrent cardiac/orthopedic/neurological disease are unlikely to receive benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The project will develop a Turkey-made digital respiratory game (DRG) and a sensing device that detect lung volume and flow and provide real-time guidance for Active Cycle of Breathing Techniques (ACBT). Clinically stable children aged 7–18 will use the home-based system on a smartphone, tablet, or computer to perform daily airway-clearing maneuvers. The DRG includes difficulty levels, storytelling, and feedback to improve engagement and adherence while measuring technique and usage. Outcomes will include adherence, quality of breathing maneuvers, and respiratory measures collected during the intervention and follow-up.
Why it matters
Potential benefit: If successful, the tool could improve daily airway clearance and adherence, reduce respiratory infections and clinic visits, and let children manage therapy at home without frequent physiotherapist supervision.
How similar studies have gone: Related digital respiratory games and home airway-clearance devices have shown promise in small pilots—particularly in cystic fibrosis—for improving adherence and technique, but evidence specifically in pediatric bronchiectasis is limited and this Turkey-developed system is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged between 7-18 years * Clinically stable * No exacerbations or infections * Possesses a computer, tablet, or mobile phone Exclusion Criteria: * Participation in a supervised physiotherapy and rehabilitation program within the last 6 months * History of lung or liver transplant * Presence of any cognitive impairment that would hinder the use of the system * Changes in medical treatment during the study * Presence of concurrent cardiac, orthopedic, or neurological diseases
Where it's running
-
Istanbul Atlas University
Istanbul, Turkey (Türkiye) Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Chronic Respiratory Disease Participant Engagement
This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.
-
Breathlessness in respiratory diseases: who feels it and why
This study tests how physiology, psychology, function, and breathing patterns relate to breathlessness in people with respiratory conditions compared with healthy controls.
-
Hypertonic saline inhalation for NTM lung disease
This trial tests whether starting inhaled 3% hypertonic saline early helps people with non-tuberculous mycobacterial lung disease feel better and clear bacteria better, compared with starting with normal saline first.
-
Azithromycin added to usual care to see if it lowers bronchiectasis flare-ups
This trial tests whether taking azithromycin daily for a year reduces bronchiectasis-related flare-ups in adults with non-cystic fibrosis bronchiectasis.
-
Bronchiectasis Phenotype Identification Model for Adults
This study tests a baseline classifier to categorize adults with non-cystic fibrosis bronchiectasis into phenotype groups using data collected over time.
-
BASE: Aiming to test a simple, objective way to gauge bronchiectasis severity and predict flare-ups
This study tests a new BASE framework to classify how severe non-cystic fibrosis bronchiectasis is right now and see if it can predict 12 months of worsening or flare-ups.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.